Aclaris Therapeutics is a company developing treatments for dermatology and immunology.
ATI-502 is a topical JAK1/JAK3 inhibitor that is being investigated (Phase 2) for alopecia areataalopecia areata, including patchy alopecia areata and the more severe forms of the disease, alopecia totalis and alopecia universalis. The product is also under investigation (Phase 2) for androgenetic alopecia, vitiligo, and atopic dermatitis. In July 2017, Aclaris filed an IND (investigational new drug) application for ATI-502.
No more activity to show.